Analysis of the influence of recent reforms in China: Cardiovascular and cerebrovascular medicines as a case history to provide future direction

Journal of Comparative Effectiveness Research

Volumn 3, Issue 4, 2014, Pages 371-386

  Zeng, Wenjie ^a   Zhen, Junjie ^a   Feng, Mengying ^a   Campbell, Stephen M ^b,c   Finlayson, Alexander E ^d   Godman, Brian ^e,f,g  

^a CHONGQING JIAOTONG UNIVERSITY   (China)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c The University of Manchester   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^g INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

cardiovascular drugs; China; demand side measures; drug utilization; generics

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CARNITINE; CEREBROVASCULAR DRUG; CHINESE DRUG; CINEPAZIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG; ENALAPRIL MALEATE; ESMOLOL; FELODIPINE; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; METOPROLOL; NIFEDIPINE; OXIRACETAM; SIMVASTATIN; TELMISARTAN; TETRAMETHYLPYRAZINE; UNCLASSIFIED DRUG; VALSARTAN;

ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHINA; CHINESE MEDICINE; DRUG COST; DRUG UTILIZATION; FUTUROLOGY; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HOSPITAL; HOSPITAL PHARMACY; HOSPITAL RUNNING COST; HUMAN; NEUTROPENIA; OBSERVATIONAL STUDY; PHYSICIAN; PRESCRIPTION; RETROSPECTIVE STUDY; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; HOSPITAL COST; TRENDS;

CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CHINA; DRUG UTILIZATION; DRUGS, GENERIC; HEALTH CARE REFORM; HOSPITAL COSTS; HUMANS; RETROSPECTIVE STUDIES;

EID: 84907816151     PISSN: 20426305     EISSN: 20426313     Source Type: Journal    
DOI: 10.2217/cer.14.28     Document Type: Article

References (64)

1. Godman B, Haycox A, Schwabe U, Joppi R, Garattini S. Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 26, 91-98 (2008
2. Godman B, Campbell S, Suh HS, Finlayson A, Bennie M, Gustafsson L. Ongoing measures to enhance prescribing efficiency across Europe: implications for other countries. J. Health Tech. Assess. 1, 27-42 (2013
3. Godman B, Bennie M, Baumgärtel C et al. Essential to increase the use of generics in Europe to maintain comprehensive healthcare?. Farmeconomia: Health Econ. Therap. Pathways 13(SUPPL 3), 5-20 (2012
4. Godman B, Shrank W, Andersen M et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilisation: changes seen and global implications. Expert Rev. Pharmacoecon. Outcomes Res. 10, 707-722 (2010
5. Godman B, Wettermark B, Bishop I et al. European payer initiatives to reduce prescribing costs through use of generics. GaBi J. 1, 22-27 (2012
6. Godman B, Sakshaug S, Berg C, Wettermark B, Haycox A. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev. Pharmacoecon. Outcomes Res. 11, 121-129 (2011
7. van Woerkom M, Piepenbrink H, Godman B et al. Ongoing measures to enhance the efficiency of prescribing of PPIs and statins in The Netherlands; influence and future implications. J. Comp. Eff. Res. 1, 527-538 (2012
8. Kaplan WA, Ritz LS, Vitello M, Wirtz VJ. Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000-2010. Health Policy 106(3), 211-224 (2012
9. Voncina L, Strizrep T, Godman B et al. Influence of demand-side measures to enhance renin-Angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev. Pharmacoecon. Outcomes Res. 11, 469-479 (2011
10. Godman B, Bishop I, Finlayson AE et al. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev. Pharmacoecon. Outcomes Res. 13(4), 469-482 (2013
11. Godman B, Malmstrom RE, Bennie M et al. Prescribing restrictions - A necessary strategy among some European countries to enhance future prescribing efficiency?. Rev. Health Care 3, 5-16 (2012
12. Bucsics A, Godman B, Burkhardt T et al. Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries. Expert Rev. Pharmacoecon. Outcomes Res. 12(6), 809-819 (2012
13. Hesse U, Godman B, Petzold M et al. Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries. Appl. Health Econ. Health Policy 1-9 (2013
14. Godman B, Wettermark B, Miranda J, Bennie M, Martin A, Malmström RE. Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries. Int. J. Clin. Prac. 67, 853-862 (2013
15. Fraeyman J, Van Hal G, Godman B et al. The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium. Expert Rev. Pharmacoecon. Outcomes Res. 13(1), 141-151 (2013
16. Martin A, Godman B, Miranda J et al. Measures to improve angiotensin receptor blocker prescribing efficiency in the UK: findings and implications. J. Comp. Eff. Res. 3(1), 41-51 (2014
17. Moon J, Flett A, Godman B et al. Getting better value from the NHS drug budget. BMJ 342, 30-32 (2011
18. Zeng W. A price and use comparison of generic versus originator cardiovascular medicines: a hospital study in Chongqing, China. BMC Health Serv. Res. 2013 13, 390 (2013
19. Meng Q, Xu L, Zhang Y et al. Trends in access to health services and financial protection in China between 2003 and 2011: a cross-sectional study. Lancet 379(9818), 805-814 (2012
20. Barber S, Yao L. Development and status of health insurance systems in China. Int. J. Health Plann. Mgmt. 26, 339-356 (2011
21. Barber S, Huang B, Santoso B, Laing R, Paris V, Wu C. The reform of the essential medicines system in China: a comprehensive approach to universal coverage. J. Glob. Health 3(1), 010303 (2013
22. Li X, Zhang W. The impacts of health insurance on health care utilization among the older people in China. Soc. Sci. Med. 85, 59-65 (2013
23. Sun J. International experiences of promoting generics use and its implications to China. J. Evid. Based Med. 6(2), 74-80 (2013
24. Li L. The challenges of healthcare reforms in China. Public Health 125, 6e8 (2011
25. Ling R, Liu F, Lu X, Wang W. Emerging issues in public health: a perspective on China's healthcare system. Public Health 125, 9e14 (2011
26. Sun Q, Santoro MA, Meng Q, Liu C, Eggleston K. Pharmaceutical policy in China. Health Aff. (Millwood) 27(4), 1042-1050 (2013
27. Yu X, Li C, Shi Y, Yu M. Pharmaceutical supply chain in China: current issues and implications for health system reform. Health Policy 97, 8-15 (2010
28. Wagstaff A, Lindelow M. Can insurance increase financial risk?. The curious case of health insurance in China. J. Health Econ. 27(4), 990-1005 (2008
29. Mao W, Tang S, Chen W. Does perverse economic incentive lead to the irrational uses of medicines?. Expert Rev. Pharmacoecon. Outcomes Res. 13(6), 693-696 (2013
30. Liu L, Lu Z, Zhang X. Analysis of rational use of drugs in community health service facilities. Chinese Health Econ. 28(4), 45-47 (2009
31. Reynolds L, McKee M. Serve the people or close the sale?. Profit-driven overuse of injections and infusions in China's market-based healthcare system. Int. J. Health Plann. Mgmt. 26, 449-470 (2011
32. Reynolds L, McKee M. Factors influencing antibiotic prescribing in China: an exploratory analysis. Health Policy 90, 32-36 (2009
33. Lu C, Ross-Degnan D, Stephens P, Liu B, Wagner A. Changes in use of antidiabetic medications following price regulations in China (1999-2009). JPHSR 4, 3-11 (2013
34. Meng Q, Cheng G, Silver L, Sun X, Rehnberg C, Tomson G. The impact of China's retail drug price control policy on hospital expenditures: a case study in two Shandong hospitals. Health Policy Plan. 20, 185-196 (2005
35. Chen Y, Schweitzer SO. Issues in Drug pricing, reimbursement, and access in China with references to other Asia-Pacific region. Value Health 11, 124-129 (2008
36. Lim D, Emery J, Lewis J, Sunderland VB. A systematic review of the literature comparing the practices of dispensing and non-dispensing doctors. Health Policy 92, 1-9 (2009
37. Jin SR, Hu L, Du L, Huang K. Analysis of drug use in 29 hospitals of Chongqing area from 2008 to 2010. China Pharm. 23, 872-876 (2012
38. Qu C, Xie H, Zhang P, Shi W. Dynamic analysis of drugs administration in some hospitals in Guangdong area during the period 2002-2005. China Pharm. 17, 1072-1074 (2006
39. Teng L, Xin HW, Blix HS, Tsutani K. Review of the use of defined daily dose concept in Drug utilisation research in China. Pharmacoepidemiol. Drug Saf. 21(10), 1118-1124 (2012
40. Ji K, Chen J, Li M et al. Comments on serious anaphylaxis caused by nine Chinese herbal injections used to treat common colds and upper respiratory tract infections. Regul. Toxicol. Pharmacol. 55(2), 134-138 (2009
41. Tao T, Xu C, Hu M, Liao W, Jiang X. Analysis of Chinese pharmaceutical price policy from 1997 to 2011. Chin. J. Health Policy 4, 46-52 (2011
42. Jingang A. Which future for doctors in China?. Lancet 382, 936-937 (2013
43. Grimshaw J, Campbell M, Eccles M et al. Experimental and quasi-experimental designs for evaluating guidelines implementation strategies. Family Pract. 17, S11-S16 (2000
44. WHO. Guidelines for ATC classification and DDD assignment. In Oslo: WHO Collaborating Centre for Drug Statistics Methodology. www.whocc.no
45. United Nations. Consolidated List of Products Whose Consumption and/or Sale have been Banned, Withdrawn, Severely Restricted or Not Approved by Governments [M] (8th Edition). United Nations Publication, NY, USA, 58 (2003
46. Yi Z, Liu F, Zhang J, Li Xi, Zhai S. Cinepazide-induced hematological adverse reactions: review and analysis. Adverse Drug React. J. 12(4), 251-254 (2010) (in Chinese
47. Vogler S, Zimmermann N, Leopold C, de Joncheere K. Pharmaceutical policies in European countries in response to the global financial crisis. South Med. Rev. 4(2), 69-79 (2011
48. Sermet C, Andrieu V, Godman B et al. Ongoing pharmaceutical reforms in France; implications for key stakeholder groups. Appl. Health Econ. Health Policy 8, 7-24 (2010
49. Kwon HY, Hong JM, Godman B et al. Price cuts and drug spending in South Korea: the case of antihyperlipidemic agents. Health Policy 112 (2013) 217-226
50. Lee IH, Bloor K, Hewitt C et al. The effects of new pricing and copayment schemes for pharmaceuticals in South Korea. Health Policy 104(1), 40-49 (2012
51. Kwon HY, Yang BM. Do generics really create savings on Drug expenditures?. Korean J. Health Econ. Policy 17(4), 23-42 (2011
52. Gustafsson LL, Wettermark B, Godman B et al. The 'Wise List'- A comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin. Pharmacol. Toxicol. 108, 224-233 (2011
53. Björkhem-Bergman J, Andersen-Karlsson E, Laing R et al. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. Eur. J. Clin. Pharmacol. 69(SUPPL 1), S73-S78 (2013
54. da Costa Lima-Dellamora E, Caetano R, Gustafsson LL. An analytical framework for assessing drug and therapeutics committee structure and work processes in tertiary Brazilian hospitals. Basic Clin. Pharmacol. Toxicol. 115(3), 268-276 (2014
55. Godman B, Wettermark B, Hoffman M et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden; global relevance. Expert Rev. Pharmacoecon. Outcomes Res. 9, 65-83 (2009
56. Norman C, Zarrinkoub R, Hasselström J et al. Potential savings without compromising the quality of care. Int. J. Clin. Pract. 63, 1320-1326 (2009
57. Wettermark B, Jacobsson B, Godman B, Haaijer-Ruskamp F. Soft regulations in pharmaceutical policymaking - An overview of current approaches and their consequences. Appl. Health Econ. Health Policy 7, 1-11 (2009
58. Hoven JL, Haaijer-Ruskamp FM, Vander Stichele RH. DURQUIM Scientific Committee. Indicators of prescribing quality in Drug utilization research: report of a European meeting (DURQUIM, 13-15 May 2004). Eur. J. Clin. Pharmacol. 60, 831-834 (2005
59. Campbell SM, Reeves D, Kontopantelis E, Sibbald B, Roland M. Impact of pay-for-performance on quality of English primary care: interrupted time series analysis. N. Eng. J. Med. 361, 368-378 (2009
60. Wettermark B, Pehrsson Å Juhasz-Haverinen M et al. Financial incentives linked to self-Assessment of prescribing patterns - A new approach for quality improvement of drug prescribing in primary care. Qual. Primary Care 17, 179-189 (2009
61. Campbell SM, Godman B, Diogene E et al. Quality indicators as a tool in improving the introduction of new medicines. Basic Clin. Pharmacol. Toxicol. (2014) (Epub ahead of print
62. Godman B, Paterson K, Malmstrom R et al. Improving the managed entry of new medicines: sharing experiences across Europe. Expert Rev. Pharmacoecon. Outcomes Res. 12, 439-441 (2012
63. Hoyle M. Future drug prices and cost-effectiveness analyses. Pharmacoeconomics 26, 589-602 (2008
64. Danzon PM, Kim JD. The Life Cycle of Pharmaceuticals: A Cross-national Perspective. London, Office of Health Economics 2002. www.opengrey.eu/item/display/10068/553731